[HTML][HTML] A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors
Although the majority of papillary thyroid cancer (PTC) is indolent, a subset of PTC behaves
aggressively despite the best available treatment. A major clinical challenge is to reliably …
aggressively despite the best available treatment. A major clinical challenge is to reliably …
A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.
Q Cheng, X Li, CR Acharya, T Hyslop, JA Sosa - Oncotarget, 2017 - escholarship.org
Although the majority of papillary thyroid cancer (PTC) is indolent, a subset of PTC behaves
aggressively despite the best available treatment. A major clinical challenge is to reliably …
aggressively despite the best available treatment. A major clinical challenge is to reliably …
A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.
Q Cheng, X Li, CR Acharya, T Hyslop, JA Sosa - Oncotarget, 2017 - europepmc.org
Although the majority of papillary thyroid cancer (PTC) is indolent, a subset of PTC behaves
aggressively despite the best available treatment. A major clinical challenge is to reliably …
aggressively despite the best available treatment. A major clinical challenge is to reliably …
[HTML][HTML] A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors
Q Cheng, X Li, CR Acharya, T Hyslop, JA Sosa - Oncotarget, 2017 - oncotarget.com
A novel integrative risk index of papillary thyroid cancer progression combining genomic
alterations and clinical factors | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home …
alterations and clinical factors | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home …
[PDF][PDF] A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors
Q Cheng, X Li, CR Acharya, T Hyslop, J Ann - pdfs.semanticscholar.org
Although the majority of papillary thyroid cancer (PTC) is indolent, a subset of PTC behaves
aggressively despite the best available treatment. A major clinical challenge is to reliably …
aggressively despite the best available treatment. A major clinical challenge is to reliably …
A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors
Q Cheng, X Li, CR Acharya, T Hyslop… - Oncotarget, 2017 - pubmed.ncbi.nlm.nih.gov
Although the majority of papillary thyroid cancer (PTC) is indolent, a subset of PTC behaves
aggressively despite the best available treatment. A major clinical challenge is to reliably …
aggressively despite the best available treatment. A major clinical challenge is to reliably …
A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors
Q Cheng, X Li, CR Acharya, T Hyslop, JA Sosa - Oncotarget, 2017 - oncotarget.com
A novel integrative risk index of papillary thyroid cancer progression combining genomic
alterations and clinical factors | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home …
alterations and clinical factors | Oncotarget Online ISSN: 1949-2553 Search: Oncotarget Home …
A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.
Q Cheng, X Li, CR Acharya, T Hyslop, JA Sosa - Oncotarget, 2017 - europepmc.org
Although the majority of papillary thyroid cancer (PTC) is indolent, a subset of PTC behaves
aggressively despite the best available treatment. A major clinical challenge is to reliably …
aggressively despite the best available treatment. A major clinical challenge is to reliably …